Related references
Note: Only part of the references are listed.OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy
Peter C. Taylor et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis
Eva Salgado et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds
Vibeke Strand et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2014)
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor-α Antagonist
Mark C. Genovese et al.
JOURNAL OF RHEUMATOLOGY (2014)
The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial
George D. Kitas et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2014)
Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
Michael E. Weinblatt et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies
Muhammad Baluom et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: A review
Maninder Kaur et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2013)
Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial
Michael E. Weinblatt et al.
JOURNAL OF RHEUMATOLOGY (2013)
An Oral Syk Kinase Inhibitor in the Treatment of Rheumatoid Arthritis A Three-Month Randomized, Placebo-Controlled, Phase II Study in Patients With Active Rheumatoid Arthritis That Did Not Respond to Biologic Agents
Mark C. Genovese et al.
ARTHRITIS AND RHEUMATISM (2011)
Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors
Devesh Mewar et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Role of Spleen Tyrosine Kinase Inhibitors in the Management of Rheumatoid Arthritis
David L. Scott
DRUGS (2011)
Fostamatinib, a Syk-Kinase Inhibitor, Does Not Affect Methotrexate Pharmacokinetics in Patients With Rheumatoid Arthritis
Muhammad Baluom et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Tyrosine kinases in rheumatoid arthritis
Hiroshi Okamoto et al.
JOURNAL OF INFLAMMATION-LONDON (2011)
From the gut to the joint
Clemens Scheinecker et al.
NATURE REVIEWS RHEUMATOLOGY (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Healing the Syk through Kinase Inhibitors.
Juan Rivera et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis.
Michael E. Weinblatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Contribution of gut bacteria to the metabolism of the spleen tyrosine kinase (Syk) inhibitor R406 in cynomolgus monkey
D. J. Sweeny et al.
XENOBIOTICA (2010)
Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis
Steven S. Storage et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2010)
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Alessandro Liberati et al.
ANNALS OF INTERNAL MEDICINE (2009)
Treatment of Rheumatoid Arthritis With a Syk Kinase Inhibitor A Twelve-Week, Randomized, Placebo-Controlled Trial
Michael E. Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2008)
GRADE:: what is quality of evidence and why is it important to clinicians?
Gordon H. Guyatt et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor
Polly R. Pine et al.
CLINICAL IMMUNOLOGY (2007)
The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey
John P. A. Ioannidis et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2007)
R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation
Sylvia Braselmann et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
A novel spleen tyrosine kinase inhibitor blocks c-jun N-terminal kinase-mediated gene expression in synoviocytes
HS Cha et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
In an empirical evaluation of the funnel plot, researchers could not visually identify publication bias
N Terrin et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2005)
Src and Syk kinases:: key regulators of phagocytic cell activation
G Berton et al.
TRENDS IN IMMUNOLOGY (2005)
Targeting Syk as a treatment for allergic and and autoimmune disorders
BR Wong et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Misleading funnel plot for detection of bias in meta-analysis
JL Tang et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2000)
Induction and suppression of collagen-induced arthritis is dependent on distinct Fcγ receptors
S Kleinau et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Tyrosine kinase SYK: essential functions for immunoreceptor signalling
M Turner et al.
IMMUNOLOGY TODAY (2000)
Share Paper
